Yale University School of Medicine other research news

Yale researchers published in Science that short-term administration of ABT 431, a dopamine D1 receptor agonist, reversed memory deficits in monkeys that had been treated with haloperidol, a dopamine D2 receptor antagonist that is used to treat schizophrenia. The improvement in memory was sustained for more than 1 year after cessation of ABT 431 treatment. The researchers suggested that transient dopamine D1 agonism could be useful to treat patients with schizophrenia or other dopamine dysfunctional conditions. ...